References
- Nordhaus W. Irving Fisher and the contribution of improved longevity to living standards. Am. J. Econ. Sociol.64(1), 367–392 (2005).
- Murphy K, Topel R. The value of health and longevity. J. Polit. Econ.14(5), 871–904 (2006).
- Lichtenberg F. Sources of U.S. longevity increase, 1960–2001. Q. Rev. Econ. Bus.44(3), 47–73 (2004).
- DiMasi J, Hansen R, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ.22(2), 151–185 (2003).
- Vernon JA, Golec J, DiMasi J. Drug development costs when financial risk is measured using the Fama–French three-factor model. Health Econ.19(8), 1002–1005 (2010).
- Golec J, Hegde S, Vernon JA. Pharmaceutical stock price reactions to price constraint threats and firm-level R&D spending. JFQA45(1), 239–264 (2010).
- Golec JH, Vernon JA. Financial risk of the biotechnology industry versus the pharmaceutical industry. Appl. Health Econ. Health Policy7(3), 155–165 (2009).
- Giaccotto C, Golec J, Vernon JA. New estimates of the cost of capital for pharmaceutical firms. JCF (2010) (In Press).
Website
- Vernon JA. Are drug prices rising too fast? http://energycommerce.house.gov/Press_111/20091208/vernon_testimony.pdf